分子在早期心力衰竭发育中的应用:微循环调节,新陈代谢,氧化应激和心肌状况
Anna Vyacheslavovna Deryugina1, Darya Andreevna Danilova1, Anastasia Vladimirovna Polozova1
1Department of Physiology and Anatomy, Institute of Biology and Biomedicine, National Research Lobachevsky State University of Nizhny Novgorod, 23 Prospekt Gagarina (Gagarin Avenue), Nizhny Novgorod 603950, Russia.
Antioxidants (Basel, Switzerland)
|December 30, 2025
概括
在慢性心力衰竭 (CHF) 的老鼠模型中,分子 (H2) 疗法改善了血液流动并减少了氧化应激. 多重治疗是最有效的,这表明有可能延迟CHF的进展.
科学领域:
- 心血管医学 心血管医学
- 生物医学工程 生物医学工程
- 氧化压力研究研究 氧化压力研究
背景情况:
- 氧化应激是慢性心力衰竭 (CHF) 发展的关键因素.
- 分子 (H2) 减轻CHF相关问题的确切机制尚不清楚.
- 了解H2对血液动力学和心肌损伤的影响对于治疗开发至关重要.
研究的目的:
- 研究单次和多次H2吸入对CHF大鼠模型的影响.
- 评估H2对心血管功能,氧化应激和心肌组织的影响.
- 为了阐明H2在早期CHF的治疗潜力.
主要方法:
- 在老鼠中通过注射甲基荷兰胺诱导CHF.
- 通过吸入给药H2 (一次40分钟的疗程和5天每天40分钟的疗程).
- 使用激光多普勒流量计和激光光谱学评估微循环功能,测量脂质过氧化,以及肌肉组织组织分析.
主要成果:
- 通过恢复本地和中央调节机制,H2吸入显著改善了微血管输液.
- 氧化应激和代谢异常被H2显著减少,在多次使用后有效性增加.
- 在重塑过程中,重复的H2吸入减轻了心肌胀,并保留了心脏组织形态.
结论:
- 水素疗法显示出延缓早期慢性心力衰竭进展的潜力.
- 2使微循环和组织代谢正常化,提供了一个有前途的治疗途径.
- 对H2的机制和在心血管疾病中的临床应用进行进一步的研究是有必要的.
相关概念视频
Heart Failure V: Medical Management
196
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
196
Cardiomyopathy V: Interprofessional Care
310
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
310
Heart Failure VI: Adjunct Therapies
233
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
233
Pathophysiology of Heart Failure
2.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.7K
Heart Failure II: Pathophysiology
663
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
663
Heart Failure I: Introduction
657
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
657

